Can I Take Resveratrol with AndroGel?

Updated Jan 28, 2025

Image: HealthRX.com clinical illustration

AndroGel (testosterone 1.62% topical gel, generic name testosterone, drug class androgen) is FDA-approved for men with confirmed hypogonadism. Resveratrol is a polyphenolic stilbene supplement (found in grape skin, Japanese knotweed, and peanuts) sold over the counter for cardiovascular and longevity claims that are themselves not FDA-evaluated. There is no FDA labeling, black-box warning, or contraindication listing resveratrol as unsafe with AndroGel.

Direct answer: Resveratrol is not a documented hard contraindication with AndroGel. Two plausible interaction mechanisms exist on pharmacological grounds, weak, dose-dependent inhibition of CYP3A4 (the enzyme pathway involved in testosterone clearance) and weak, tissue-selective binding to estrogen receptors, but the clinical magnitude of either effect in men actually taking AndroGel has not been established in dedicated trials. This is a plausibility-based caution, not a proven interaction, and it should be treated that way rather than as settled fact.

Who takes AndroGel, and why does this question come up

AndroGel is prescribed for male hypogonadism, generally defined as low morning serum total testosterone confirmed on two separate draws along with symptoms of androgen deficiency. Men on testosterone replacement therapy (TRT) already undergo periodic hormone and hematocrit monitoring, and many add over-the-counter supplements like resveratrol for reasons unrelated to their TRT (cardiovascular support, general antioxidant use) without necessarily discussing the addition with their prescriber. That gap between supplement use and clinical awareness is the real-world reason this interaction question matters, more than any single alarming data point.

Transdermal testosterone from AndroGel is absorbed through the skin and enters systemic circulation without first-pass hepatic metabolism. Clearance, however, still runs largely through hepatic CYP3A4. That distinction matters: resveratrol's effect on CYP3A4, if clinically meaningful, would act mainly on clearance rather than on absorption from the gel itself.

What is established about resveratrol and CYP3A4

In vitro and small clinical pharmacology studies have reported that resveratrol can inhibit CYP3A4 activity, and this effect appears dose-dependent, more pronounced at gram-level doses than at the 100 to 500 mg/day range typically used in over-the-counter supplements. Because oral resveratrol undergoes extensive first-pass glucuronidation, plasma concentrations at typical supplement doses are low relative to the concentrations used in laboratory inhibition studies, which is one reason clinical pharmacologists generally regard the interaction as a mild, dose-dependent effect rather than a strong one. The specific inhibitory potency figures and trial sample sizes attributed to this pathway in older summaries of this topic could not be verified against a specific, checkable primary source for this article and should not be treated as precise numbers pending direct review of the original literature.

If CYP3A4-mediated clearance of testosterone is slowed, the plausible downstream effects are a modest rise in circulating testosterone and, through aromatization, a parallel rise in estradiol. Whether this occurs to a measurable degree at typical AndroGel doses combined with typical resveratrol doses has not been directly studied in a dedicated interaction trial, as far as this review could confirm.

What is established about resveratrol and estrogen receptors

Resveratrol binds estrogen receptor alpha and beta with low affinity relative to estradiol itself, and laboratory studies describe it as behaving like a partial, tissue-selective modulator (comparable in concept, not potency, to a SERM such as tamoxifen). This is consistent, mechanistically documented pharmacology. What is not established is whether this weak receptor activity produces any clinically noticeable shift in the testosterone-to-estradiol balance in men who are also receiving exogenous testosterone. Small human trials of resveratrol in men have reported inconsistent effects on testosterone and estradiol, including at least one report of resveratrol modestly lowering testosterone rather than raising it. Those trial identities and exact effect sizes referenced in earlier drafts of this topic could not be independently verified here and should be confirmed against the primary literature before being repeated as fact.

This is the strongest, most quotable summary this evidence supports: resveratrol has a documented, dose-dependent inhibitory effect on CYP3A4 and a documented, weak, tissue-selective estrogen receptor activity in laboratory and small human studies, but no dedicated clinical trial has measured the combined effect of resveratrol and testosterone gel on hormone levels in hypogonadal men, so the practical size of either effect at typical supplement doses remains unproven rather than disproven.

Evidence-status interaction assessment

Status	Claim	What this means for a reader
Established	AndroGel requires baseline and periodic monitoring of testosterone, estradiol, hematocrit, and PSA per its FDA label and standard endocrinology practice.	Any supplement addition should piggyback on this existing monitoring schedule, not replace it.
Established	Resveratrol inhibits CYP3A4 in vitro and in some human pharmacology studies, in a dose-dependent way.	Higher-dose resveratrol (roughly gram-level, well above typical 100 to 500 mg/day supplement doses) carries more theoretical clearance-related risk than low-dose use.
Established	Resveratrol has weak, tissue-selective estrogen receptor binding activity.	The mechanism for an estrogenic effect exists, but affinity is far below that of estradiol itself.
Plausible but unproven	Combining resveratrol with AndroGel could produce a small rise in testosterone and estradiol via slowed clearance.	Worth checking labs for, not worth assuming will happen.
Plausible but unproven	Resveratrol's estrogen receptor activity could modestly aggravate estrogen-sensitive symptoms (breast tenderness) in men already running high estradiol on TRT.	Relevant mainly to men with a prior history of elevated estradiol or gynecomastia symptoms.
Not established	Any specific numeric threshold (a precise resveratrol milligram dose, inhibitory constant, or percentage change in testosterone/estradiol) for this specific combination.	Treat any precise number you see elsewhere on this topic as unverified until it is checked against a primary trial or the FDA label.
Requires clinician/pharmacist verification	Whether a specific patient's other medications (aromatase inhibitors, azole antifungals, warfarin, daily grapefruit juice) stack with resveratrol's CYP3A4 or antiplatelet effects.	This is a pharmacist-level medication reconciliation question, not something to resolve from a general article.

Should you stop resveratrol before starting or continuing AndroGel

There is no FDA or guideline-based requirement to stop resveratrol before starting AndroGel, and no evidence in this review supports discontinuing it purely because the two are being combined. A more defensible approach is to treat resveratrol like any other variable that could shift hormone monitoring results: mention it to the prescriber, keep the dose consistent, and let the next scheduled hormone panel (rather than an early, unscheduled one) capture whether anything meaningful has changed, unless new symptoms appear sooner.

Report the following to a prescriber promptly rather than waiting for the next routine visit: new breast tenderness or nipple sensitivity, unexplained rapid weight gain or fluid retention, worsening sleep apnea symptoms, or any bleeding or bruising that is new if resveratrol is being combined with an anticoagulant. These are reasons to seek prompt clinical evaluation, not emergency symptoms on their own, but they should not wait for a routine annual visit.

Situations that raise the risk calculus

The interaction question changes if any of the following apply, and these situations deserve a direct conversation with a prescriber or pharmacist rather than self-management:

Concurrent aromatase inhibitor use (for example anastrozole), where estradiol is already being pharmacologically manipulated and adding a weak estrogen receptor ligand and CYP3A4 inhibitor complicates the picture.
Concurrent strong CYP3A4 inhibitors such as azole antifungals, where resveratrol's effect could be additive.
Anticoagulant use (warfarin, direct oral anticoagulants), since AndroGel's own label warns that androgens can increase anticoagulant sensitivity, and resveratrol has reported antiplatelet activity at high doses.
Baseline elevated estradiol, gynecomastia, or polycythemia, where any additional variable that could nudge estradiol or hematocrit deserves closer tracking.
High-dose resveratrol use (multi-gram daily doses used in some research protocols), which is a different exposure than typical 100 to 500 mg over-the-counter supplement use and carries more plausible pharmacokinetic effect.

Evidence boundary

What is established: AndroGel's FDA label requires baseline and periodic monitoring of testosterone, estradiol, hematocrit, and PSA, and warns about increased anticoagulant sensitivity. Resveratrol has documented, dose-dependent CYP3A4 inhibitory activity and documented weak estrogen receptor binding in laboratory and small human pharmacology studies.

What is plausible but unproven: that typical over-the-counter resveratrol doses meaningfully change testosterone or estradiol levels in men using AndroGel specifically.

What is not established: any specific numeric interaction threshold, effect size, or monitoring interval unique to the resveratrol-AndroGel combination. No dedicated clinical trial of this specific combination in hypogonadal men on testosterone gel was located for this review.

What requires verification before acting on it: any precise dose, potency constant, or percentage figure attached to this interaction elsewhere online, including in earlier versions of material like this. A pharmacist or prescriber reviewing an individual's full medication list is the appropriate person to weigh in on a specific case.

A reasonable practical approach

Tell your prescriber or pharmacist that you take resveratrol, including the dose, at your next TRT visit rather than waiting to be asked.
Keep resveratrol dosing consistent rather than changing it around lab draw dates, so your labs reflect your actual routine.
Let your existing AndroGel monitoring schedule (hormone panel and hematocrit at the intervals your prescriber has set) do the work, rather than requesting extra unscheduled labs unless new symptoms appear.
Flag any new breast tenderness, fluid retention, or bleeding symptoms promptly instead of waiting for a routine visit.
If you are also on an aromatase inhibitor, an azole antifungal, or an anticoagulant, raise resveratrol specifically with your prescriber or pharmacist before continuing it, since these combinations are the ones with the clearest plausible mechanism for a meaningful effect.

Frequently asked questions

Can I take resveratrol while on AndroGel?

There is no FDA contraindication against it. The combination has a plausible but unproven pharmacological interaction (CYP3A4 inhibition and weak estrogen receptor activity from resveratrol), so mentioning it to your prescriber and keeping it within your existing hormone monitoring schedule is a reasonable approach.

Does resveratrol interact with AndroGel?

Two mechanisms are plausible: resveratrol's dose-dependent inhibition of CYP3A4, an enzyme involved in testosterone clearance, and resveratrol's weak, tissue-selective estrogen receptor activity. Neither has been studied directly in men using AndroGel, so the real-world size of the effect is unproven rather than disproven.

Will resveratrol raise my testosterone while on AndroGel?

This is not established. Small human trials of resveratrol alone have reported inconsistent effects on testosterone, including at least one report of a decrease rather than an increase. Individual lab monitoring is more informative than a general prediction.

Can resveratrol raise estrogen in men on testosterone?

It is mechanistically plausible through two routes, slowed testosterone clearance via CYP3A4 inhibition and direct weak estrogen receptor binding, but the clinical magnitude at typical over-the-counter doses has not been established in men on testosterone therapy specifically.

Do I need to separate the timing of my AndroGel and resveratrol doses?

No dose-separation window is supported by the pharmacology here. AndroGel is absorbed transdermally and cleared systemically rather than through the gastrointestinal tract, so oral resveratrol timing relative to gel application is not expected to change absorption.

Should I stop resveratrol before my TRT blood test?

No. Your prescriber needs your labs to reflect your actual routine, including any supplements you take regularly. Tell your prescriber you take resveratrol when reviewing results instead of stopping it beforehand.

Is this interaction a concern if I'm also on an aromatase inhibitor or anticoagulant?

Yes, this is the situation that most changes the risk calculus. Aromatase inhibitors, azole antifungals, and anticoagulants each have a plausible additive interaction with resveratrol's CYP3A4 or antiplatelet effects, and this combination should be discussed directly with a prescriber or pharmacist rather than managed independently.

References

AbbVie Inc. AndroGel (testosterone gel) 1.62% prescribing information. U.S. Food and Drug Administration.

Note for editorial and clinical review: the numeric potency values, trial sample sizes, and quoted guideline language present in earlier versions of this topic could not be verified against a checkable primary source and have been removed or converted into general, hedged statements. Please confirm any specific trial citations against the original literature before restoring precise figures, and confirm current Endocrine Society or equivalent guideline language directly from the guideline document rather than from a secondary summary.